Tissue Genetics Products

Our products will establish a new paradigm for screening for hereditary disease by offering easy, accurate, cost-effective, immunohistochemistry (IHC) tests that provide significant benefits for all constituents.

Our diagnostic tests are prescribed by the oncologist or surgeon and the tests are performed in our CLIA/CAP approved lab with results the same day. Insurance reimbursement is established for immunohistochemistry tests.

The first products based on our proprietary technology will address significant market needs in the diagnosis and treatment of breast, ovarian and colorectal cancers. These products will change the standard protocols for screening of these significant diseases. No other technology can approach the benefits that we provide:

Faster - results in 48 hours
Easier - simple IHC test performed in our CLIA/CAP approved lab
Accurate - clear positive or negative results with 95% sensitivity & 98% specificity

Identify Hereditary Breast & Ovarian Cancers
BRCAssured is a novel way to screen for BRCA gene mutations thereby confirming hereditary breast & ovarian cancer. Confirming that a patient’s cancer is caused by a BRCA mutation allows critical decision-making at the time of biopsy.

Identify Hereditary Colorectal Cancers
CRCertain is a novel way to screen for Hereditary Non-Polyposis Colorectal Cancer (“HNPCC” or the “Lynch Syndrome”). Our test uniquely identifies the presence of particular gene mutations thereby confirming the disease as hereditary. Confirming that a patient’s cancer is caused by an HNPCC mutation allows critical decision-making at the time of biopsy.

Identify Cancer Patients for PARP Inhibitor Treatment
PARPcertain is a novel way to identify breast & ovarian cancer patients who will respond to an exciting new class of drug therapy – PARP Inhibitors. Early confirmation that a patient will respond to PARP Inhibitor drug treatment will save lives and reduce time, costs, toxicity and unnecessary treatments. PARPcertain will identify responders in a matter of hours using the patient’s original tissue biopsy.